Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Tecentriq / Tecentriq Hybreza
Generic name : Atezolizumab
Manufactured By : Genentech, Inc. (Roche)
Indications : Adjuvant treatment of Stage III mismatch repair deficient (dMMR) colon cancer in eligible patients.
Medicine Description : An immunotherapy for eligible patients with Stage III mismatch repair deficient (dMMR) colon cancer. Tecentriq (Atezolizumab) works by blocking the PD-L1 protein, helping the immune system recognise and attack cancer cells.
Tecentriq (Atezolizumab) and Tecentriq Hybreza (Atezolizumab + Hyaluronidase-tqjs) are immunotherapy treatments used with fluoropyrimidine and oxaliplatin chemotherapy for Stage III dMMR colon cancer after surgery.
Atezolizumab blocks the PD-L1 protein, helping the immune system recognise and attack cancer cells.
Tecentriq is approved for adults and children aged 2 years and older with Stage III dMMR colon cancer. Tecentriq Hybreza is approved for adults and eligible children aged 12 years and older weighing at least 40 kg.
Tecentriq is administered through an intravenous infusion, while Tecentriq Hybreza is injected under the skin of the thigh by a healthcare professional. Both are given with prescribed chemotherapy.
Common side effects may include nausea, diarrhoea, fatigue, constipation, decreased appetite, abdominal pain, rash, vomiting, cough and peripheral neuropathy.
Yes. Serious side effects may include immune-mediated inflammation of the lungs, liver, intestines, kidneys and hormone-producing glands, as well as severe infusion reactions.
Treatment generally involves six months of atezolizumab with chemotherapy, followed by six months of atezolizumab alone, or until disease recurrence or unacceptable toxicity.
Consult your doctor before consuming alcohol during treatment. Avoid excessive alcohol consumption, particularly if you experience treatment-related side effects.
Atezolizumab may harm an unborn baby. Avoid pregnancy during treatment and use effective contraception during treatment and for at least 5 months after the last dose.
Atezolizumab may interact with other treatments or affect immune-related conditions. Inform your doctor about all medicines, supplements and previous treatments.
If you miss a scheduled infusion or injection, contact your healthcare provider as soon as possible to arrange the next dose. Do not attempt to make up a dose yourself.
Tecentriq and Tecentriq Hybreza are administered by healthcare professionals, so food intake does not affect their administration.
Inform your doctor about autoimmune diseases, organ transplants or previous immune-related conditions. Attend regular blood tests and report persistent diarrhoea, breathing difficulties or unusual fatigue.
Store unopened Tecentriq and Tecentriq Hybreza vials in a refrigerator between 2°C and 8°C. Keep them in their original cartons, protect from light and do not freeze.
Pharma Five may assist patients seeking Tecentriq or Tecentriq Hybreza through pharmaceutical consultancy and medicine import support, subject to applicable regulations and required medical documentation. Pharma Five assists in its procurement.